Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Carcinoma, Neuroendocrine × pertuzumab × 90 days × Clear all

Sponsor

Conditions

Breast Neoplasms 24 Neoplasms 5 Neoplasm Metastasis 3 Multiple Myeloma 2 Lymphoma, Non-Hodgkin 2 Inflammatory Breast Neoplasms 2 HER2-positive Early Breast Cancer 2 HER2-positive Breast Cancer 2 Endometrial Neoplasms 2 Colonic Neoplasms 2 Anatomic Stage I Breast Cancer AJCC v8 2 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Solid Tumors 1 Solid Cancer 1 Resectable HER2-positive Breast Cancer 1 Recurrence 1 Rectal Neoplasms 1 Prostatic Neoplasms 1 Patient Preference 1 Pathologic Complete Response 1 Meningeal Neoplasms 1 Meningeal Carcinomatosis 1 Malignant Solid Neoplasm 1 Liver Neoplasms 1 Hemangiosarcoma 1 HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients 1 HER2-positive Early-stage Breast Cancer 1 Gastrointestinal Neoplasms 1 Early-stage or Locally Advanced HER2-positive Breast Cancer 1

Interventions

atezolizumab 3 Etoposide 2 Cisplatin 2 zimberelimab 1 tivozanib 1 durvalumab 1 cabozantinib 1 belinostat 1 Temozolomide 1 Standard of Care 1 Positron Emission Tomography Computed Tomography 1 Nivolumab 1 Magnetic Resonance Imaging 1 Ipilimumab 1 Immunoglobulin G 1 Disulfides 1 Carboplatin 1 Capecitabine 1 CTLA-4 Antigen 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡